LIBTAYO study results

LIBTAYO helped shrink tumors in some clinical trial patients.

In a clinical trial which included patients with locally advanced BCC who had been previously treated with a hedgehog inhibitor (HHl):

24 out of 84 patients (29%)
saw an improvement in their locally advanced BCC with LIBTAYO

Of these patients,
19 out of 84 patients (23%)
saw tumors shrink (partial response)
5 out of 84 patients (6%)
saw tumors disappear completely (complete response)
LIBTAYO® (cemiplimab-rwlc) duration of response
  • Responses lasted between 2.1 months and 21.4+ months; plus sign [+] means this patient was still responding to treatment at their last assessment

Review the most common side effects of LIBTAYO in this study.